Binding of Dopamine D1 Receptor and Noradrenaline Transporter in Individuals with Autism Spectrum Disorder: A PET Study.

Adult Autism Spectrum Disorder / metabolism Brain / metabolism Humans Male Norepinephrine Plasma Membrane Transport Proteins / metabolism Positron-Emission Tomography Receptors, Dopamine D1 / metabolism
ASD attention cognition norepinephrine positron emission tomography

Journal

Cerebral cortex (New York, N.Y. : 1991)
ISSN: 1460-2199
Titre abrégé: Cereb Cortex
Pays: United States
ID NLM: 9110718

Informations de publication

Date de publication:
03 11 2020
Historique:
received: 08 06 2020
revised: 26 06 2020
accepted: 14 07 2020
pubmed: 10 8 2020
medline: 16 12 2021
entrez: 10 8 2020
Statut: ppublish

Résumé

Although previous studies have suggested the involvement of dopamine (DA) and noradrenaline (NA) neurotransmissions in the autism spectrum disorder (ASD) pathophysiology, few studies have examined these neurotransmissions in individuals with ASD in vivo. Here, we investigated DA D1 receptor (D1R) and noradrenaline transporter (NAT) binding in adults with ASD (n = 18) and neurotypical controls (n = 20) by utilizing two different PET radioligands, [11C]SCH23390 and (S,S)-[18F]FMeNER-D2, respectively. We found no significant group differences in DA D1R (striatum, anterior cingulate cortex, and temporal cortex) or NAT (thalamus and pons) binding. However, in the ASD group, there were significant negative correlations between DA D1R binding (striatum, anterior cingulate cortex and temporal cortex) and the "attention to detail" subscale score of the Autism Spectrum Quotient. Further, there was a significant positive correlation between DA D1R binding (temporal cortex) and emotion perception ability assessed by the neurocognitive battery. Associations of NAT binding with empathic abilities and executive function were found in controls, but were absent in the ASD group. Although a lack of significant group differences in binding might be partly due to the heterogeneity of ASD, our results indicate that central DA and NA function might play certain roles in the clinical characteristics of ASD.

Identifiants

DOI: 10.1093/cercor/bhaa211 PMID: 32770189
pubmed: 32770189
pii: 5882176
doi: 10.1093/cercor/bhaa211
doi:

Substances chimiques

Norepinephrine Plasma Membrane Transport Proteins 0
Receptors, Dopamine D1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6458-6468

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press.

Auteurs

Manabu Kubota (M)

Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.
Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.
Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.

Junya Fujino (J)

Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.
Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.

Shisei Tei (S)

Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.
Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Institute of Applied Brain Sciences, Waseda University, Saitama 359-1192, Japan.
School of Human and Social Sciences, Tokyo International University, Saitama 350-1198, Japan.

Keisuke Takahata (K)

Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan.

Kiwamu Matsuoka (K)

Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.

Kenji Tagai (K)

Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.

Yasunori Sano (Y)

Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan.

Yasuharu Yamamoto (Y)

Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan.

Hitoshi Shimada (H)

Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.

Yuhei Takado (Y)

Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.

Chie Seki (C)

Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.

Takashi Itahashi (T)

Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.

Yuta Y Aoki (YY)

Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.

Haruhisa Ohta (H)

Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.
Department of Psychiatry, School of Medicine, Showa University, Tokyo 157-8577, Japan.

Ryu-Ichiro Hashimoto (RI)

Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.
Department of Language Sciences, Graduate School of Humanities, Tokyo Metropolitan University, Tokyo 192-0397, Japan.

Ming-Rong Zhang (MR)

Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.

Tetsuya Suhara (T)

Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.

Motoaki Nakamura (M)

Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.
Kanagawa Psychiatric Center, Yokohama, Kanagawa 233-0006, Japan.

Hidehiko Takahashi (H)

Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.
Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.

Nobumasa Kato (N)

Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.

Makoto Higuchi (M)

Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Binding of Dopamine D1 Receptor and...
questionsmedicales.fr › Troubles mentaux › Troubles du développement neurologique › Troubles généralisés du développement de l'enfant › Trouble du spectre autistique › Binding of Dopamine D1 Receptor and...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Binding of Dopamine D1 Receptor and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Binding of Dopamine D1 Receptor and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Protéines transporteurs de solutés › Transporteurs de la norépinéphrine › Binding of Dopamine D1 Receptor and...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Binding of Dopamine D1 Receptor and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs catécholaminergiques › Récepteurs dopaminergiques › Récepteur dopamine D1 › Binding of Dopamine D1 Receptor and...